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Abstract
Tumor-specific adenoviral vectors comprise a fruitful gene-based diagnostic imaging and therapy research area for
advanced stage of cancer, including metastatic disease. However, clinical translation of viral vectors has
encountered considerable obstacles, largely due to host immune responses against the virus. Here, we explored the
utilization of an immunosuppressant, rapamycin, to circumvent the anti-adenovirus immunity in immunocompetent
murine prostate cancer models. Rapamycin diminished adenoviral-induced acute immune response by inhibiting NF-
κB activation; it also reduced the scale and delayed the onset of inflammatory cytokine secretion. Further, we found
that rapamycin abrogated anti-adenovirus antibody production and retarded the function of myeloid cells and
lymphocytes that were activated upon viral administration in pre-immunized hosts. Thus, the co-administration of
rapamycin prolonged and enhanced adenovirus-delivered transgene expression in vivo, and thereby augmented the
imaging capability of adenoviral vectors in both bioluminescent and positron emission tomography modalities.
Furthermore, we showed that despite an excellent response of cancer cells to a cytotoxic gene therapeutic vector in
vitro, only minimal therapeutic effects were observed in vivo in pre-immunized mice. However, when we combined
gene therapy with transient immunosuppression, complete tumor growth arrest was achieved. Overall, transient
immunosuppression by rapamycin was able to boost the diagnostic utility and therapeutic potentials of adenoviral
vectors.
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Introduction
Adenoviral vectors (Ads) are widely used as in vivo gene
delivery agents in preclinical and clinical settings, for both
cancer diagnostic and therapeutic purposes [1,2]. Recently, our
group has demonstrated the ability of Ads to specifically detect
cancer metastasis following lymphatic-directed or systemic viral
administration [2,3]. Despite these encouraging results in
animal models, several hurdles need to be overcome before
the implementation of Ads in clinical applications, the most
formidable obstacle being the host immune responses against
Ad (reviewed by [4]). Previous studies with rodents and non-
human primates have shown that systemically injected Ad
(serotype 5) predominantly localized to the liver and infected
Kupffer cells, endothelial cells and hepatocytes [5–7]. Ad
infection of these cells and splenic dendritic cells (DCs) initiates
an avalanche of inflammatory cytokines and chemokines
characterized by early induction of interleukin (IL)-1 and tumor
necrosis factor (TNF)-α [8,9] followed by IL-2, IL-6,
macrophage inflammatory protein-2 (IL-8), regulated and
normal T cell expressed and secreted (RANTES), IL-12 and
interferon (IFN-γ) [10–15]. These factors in turn could recruit
and activate effector cells including neutrophils, monocytes,
polymorphonucleocytes and Vα14 invariant natural killer (NK)
cells, which could lead to tissue (mainly hepatic) damages,
aseptic shock and even death [16–18].
While Ad incurs inflammatory insults upon hosts by triggering
innate immune reactions [5,7,19], the adaptive immune system
can also clear out the virus and virally transduced cells,
impairing the effectiveness of Ad-based imaging and
therapeutic approaches [18,20,21]. Furthermore, the majority of
human population possesses anti-Ad antibodies due to
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ubiquitous exposure to this pathogen; consequently, repeated
administration of Ad vectors would prime the expansion of Ad-
specific plasma cells, leading to vigorous secondary antibody
secretion and subsequent viral clearance, reducing vector
bioavailability and potentiating host toxicity [12,20]. In addition,
transgene-expressing cells will encounter cell-mediated
immune clearance [22–24]. Notably, such elimination is not
limited to Ad directed immunity but can be also associated with
the introduced foreign transgene if the gene product is
immunogenic [19]. Since most imaging and therapeutic genes
are exogenous to the host, this immunogenicity issue
constitutes a significant challenge for achieving successful
outcome of Ad-based diagnosis and gene therapy.
In this study, we adopted an FDA-approved
immunosuppressant, rapamycin (RAPA), to assess the value of
transient immunosuppression in reconciling these conflicts
between Ad and the host immune system. RAPA binds to
FKBP12 (FK binding protein 12) and inhibits the activity of
mTOR kinase complex 1, an enzyme complex vital to a wide
range of cellular functions required for rapidly proliferating cells
[25,26]. RAPA hampers cell cycle progression (G1/S),
proliferation, activation and differentiation of T and B
lymphocytes elicited in response to a variety of stimulants as
well as the response of DCs and other innate immune cells to
inflammatory cues [27–30]. Furthermore, RAPA exhibits
appreciable anti-angiogenesis and anti-cancer properties
[20,31]. In this study, we report that rapamycin successfully
diminished Ad-associated innate and adaptive immune
responses in immunocompetent hosts using two pre-
immunized mouse strains. The strategy taken here could serve
as a platform to improve the safety profile and transgene
expression efficiency for Ad mediated molecular imaging and
therapies.
Materials and Methods
Cell culture, adenovirus and drugs
Murine prostate cancer cell lines RM-9 (a kind gift from Dr.
Timothy C. Thompson, Baylor College of Medicine [32]) and
MycCaP (a kind gift from Dr. Charles Sawyers [33]) were
cultured in DMEM medium containing 10% fetal bovine serum
and 1% penicillin/streptomycin. Intraperitoneal (i.p.) dose of
rapamycin (LC Laboratories, Woburn, MA) was dissolved in
sterile DMSO and used at indicated concentrations. Orally
applied Rapamune was purchased from Wyeth
Pharmaceuticals Inc, Philadelphia, PA. Ganciclovir (GCV)
(Cytovene-IV; Genentech, Roche group, South San
Franscisco, CA) was reconstituted with sterile water, diluted
with sterile saline and used at 50 mg/kg/day for in vivo
experiments or indicated dose for in vitro experiments.
Ad serotype 5 vectors were constructed based on a modified
AdEasy system – the AdNUEZ system, in which transgenes
can be placed into the E3 region by multiple cloning sites.
Homologous recombination of pAdEZ and pShuttle was
realized in E. Coli BJ5183 competent cells. Viral clones were
screened, propagated, purified and titered as previously
described [3]. All Ads used in this study are replication-
deficient. The empty Ad contains E1- and E3-deleted viral
backbone, with no transgenes. The titer of all Ad vectors was
determined by plaque assays, hence the plaque forming unit
(PFU).
For GCV in vitro susceptibility assay, RM-9 and MycCap
cells were infected by Ads at multiplicity of infection (MOI) of
100 and treated with GCV from day 2 to day 7 post infection
(p.i.). Cell viability was measured using Cell Counting Kit-8
(CCK-8) according to manufacturer’s instruction (Dojindo
Laboratories, Japan).
Innate immune response experiments
All animal experiments were performed in accordance with
the UCLA Institutional Animal Care and Use Committee, known
as the Chancellor’s Animal Research Committee (ARC),
guidelines (ARC # 2002-049-33; approved through 3/20/2014).
4-5-week-old BALB/c mice (Taconic Farms, Germantown, NY)
were given daily oral treatment of Rapamune (30 mg/kg;
Wyeth, Madison, NJ) 3 days prior to the intravenous (i.v.) viral
injection. Serum samples from mice were collected and
cytokine ELISA was performed according to manufacturer’s
instructions (Mouse cytokine ELISA Kit, BD Biosciences). Mice
liver tissues were lysed and subjected to western blot. Rabbit
anti-IκB-α (Santa Cruz Biotechnology, Santa Cruz, CA), anti-β
actin (Sigma, St. Louis, MO), horseradish peroxidase-
conjugated anti-rabbit and anti-mouse secondary antibodies
(Santa Cruz) were used.
SCID and immunocompetent animal comparison
experiment
5-6-week-old male SCID and BALB/c129 mice (Taconic
Farms) were treated with daily oral Rapamune for 3 days and
then intraprostatically injected with 2×108 PFU of Firefly
luciferase (FL)-expressing Ad. Luciferase expression was
monitored using an IVIS cooled CCD camera (Xenogen,
Alameda, CA). Images were analyzed with IGOR-PRO
LivingImage Software (Xenogen).
PET imaging experiment
RM-9 cells were implanted subcutaneously on the right
shoulder of male C57BL/6 mice (Taconic Farms), which, 7
days later, received oral saline or Rapamune treatment for 4
days. 5×108 PFU sr39tk-expressing Ad was then intratumorally
injected and 6 days later mice were subjected to PET imaging
with 18F-FHBG as previously described [3]. A 10-minute CAT
imaging session followed to provide structural information.
Imaging experiments in pre-immunized models
4- to 5-week-old C57BL/6 and FVB mice (Taconic Farms)
were implanted with RM-9 or MycCaP tumors, respectively. In
both models, animals were pre-exposed to Ad by i.p. injection
of 1×108 PFU of the empty virus. Three weeks after the primary
viral exposure, 2.5×105 RM-9 cells or 3×106 MycCaP cells were
then implanted subcutaneously onto the right flank of animals
in matrigel (1: 1 v/v; BD Biosciences). Indicated dose (for
C57BL/6) or 5 mg/kg (for FVB) daily i.p. RAPA or diluents
treatment started when tumor were palpable (~(5mm)3) and 3
days later, animals received intratumoral injection of 1×108
Rapamycin in Ad-Based Cancer Imaging and Therapy
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 PFU (for C57BL/6) or 5.42×108 PFU (for FVB) FL-expressing
Ads. Animals received continued daily RAPA or diluents
treatment until the end of the study. Bioluminescent imaging
was performed at indicated time points as described above.
Immunofluorescent staining
Subcutaneous tumors were dissected and fixed in histology
cassette in 3% paraformaldehyde at 4 °C overnight. Paraffin
embedded tumor sections (5 µm) were made at the pathology
lab at UCLA. Anti-F4/80 (1:500; Serotec, Raleigh, NC) and
anti-CD31 (1:300; BD Biosciences, Bedford, MA) antibodies
were used to stain the tumor sections. Pictures were taken
using Eclipse 90i microscope from Nikon.
Flow cytometry of tumors
Subcutaneous tumors were dissected and dissociated by
physically chopping and collagenase treatment (Invitrogen,
Carlsbad, CA; 80 unit/mL in DMEM media containing 10%
FBS) at 37 °C for 1.5 hours. Myeloid cells are defined by
CD11b and CSF1R staining while lymphocytes are defined as
CD11b- CD4+ or CD11b- CD8+. To make the “stimulation”
medium used in the T cell reactivity experiment, 7.6×106
MycCaP cells were infected with 3.8×107 PFU FL-expressing
Ad; 36 hours later, cells were harvested in 200 µL passive lysis
buffer (Promega, Madison, WI), subjected to three cycles of
freeze-and-thaw and centrifuged. The stimulation medium
contained 120 µg/mL cell lysate and 3×107 PFU/mL empty
virus. Cell suspensions from dissociated tumors were then
incubated with plain or this stimulation medium at 37 °C for 3.5
hours. All flow cytometry antibodies were purchased from BD
Biosciences.
Therapeutic studies
4- to 5-week-old male FVB mice (Taconic Farms) were pre-
exposed to Ad by an i.p. injection of 1×108 PFU of the empty
virus. 3 weeks later, 3×106 MycCap cells were implanted
subcutaneously onto the right flank of animals in a 1: 1 v/v mix
of sterile PBS and matrigel (BD Biosciences). The tumors
became palpable (~(5mm)3) five days later and daily i.p. RAPA
or diluent treatment was started for four consecutive days.
Animals then received intratumoral injection of 6×108 PFU
control (FL-expressing) or therapeutic Ads. RAPA or diluent
treatment was then continued for 7 days. 50 mg/kg/day GCV
was administered to the therapeutic cohorts starting day 1 post
viral injection. Tumors were measured by a caliper twice a
week till the end of the study. Animals were euthanized 30
days after tumor implantation.
Anti-adenovirus antibody titration
Mouse serum was obtained before viral administration and at
the end point of the study by retro-orbital bleeding followed by
centrifugation in a table-top centrifuge at 8000 rounds per
minute for 10 minutes. 96-well plates were coated with 1.5×107
PFU/well adenovirus in 100 µL of sodium carbonate buffer (0.1
mol/L, pH 8.8) and incubated at 4 °C overnight. At the time of
assay, the viral solution was removed and the plate was
incubated with 6% blocking reagent (Roche, Indianapolis, IN) in
0.05% PBS-Tween at 37 °C for 1 hour. Serial dilutions of
mouse serum was made in duplicate and incubated at 37 °C for
2 hours, followed by 5 times of wash with 0.5% PBS-Tween.
Biotinylated goat anti-mouse IgM and IgG (Vector Laboratories,
Inc, Burlingame, CA) antibodies were used to incubate the
plate at room temperature for 1 hour followed by 5 times of
wash. Streptavidin-HRP (PerkinElmer, Boston, MA) was then
used to incubate the plate at room temperature for 30 minutes,
followed by washes and development with TMB substrate
(Thermo scientific, Rockford, IL). The optical density of the
plate was then read at 450 nm wavelength. The anti-
adenovirus antibody titer was determined as the highest
dilution at which the post-viral serum has a reading of 0.05
greater than the corresponding pre-viral serum.
Statistical analysis
Statistical analyses were performed using unpaired or paired
two-tailed t test. For all analyses, P<0.05 was considered
statistically significant.
Results
Rapamycin diminished Ad-elicited innate immune
responses
Depending on the target cell type and cell entry mechanism,
Ad infection can trigger a diverse repertoire of signaling
molecules, including lipid kinase PI3K, mitogen-activated
protein kinase (MAPK), focal adhesion kinase-ERK1/2, and
JAK-STAT pathways [4,5,8,11]. Nuclear factor (NF)-κB is a
common downstream effector for activation of multiple
signaling pathways [8]. We first asked, by interrogating the
degradation of its inhibitor IκB, if RAPA could diminish Ad-
induced NF-κB activation. We injected saline or 1×109 PFU of
Ad intravenously (i.v.) into diluent control or RAPA-treated
BALB/c mice, harvested liver tissue at indicated time points
and subjected them to western blot. As shown in Figure 1A, Ad
caused pronounced IκB degradation (and thus NF-κB
activation) at 6 and 12 hours post injection (p.i.); RAPA
abrogated this effect.
Since NF-κB activity is linked to the transcription of many
inflammatory factors, the results in Figure 1A suggested that
RAPA could effectively mitigate the Ad-elicited cytokine storm
in the animals. To follow this issue further, we examined the
serum levels of a panel of cytokines and chemokines from
these mice. IL-1 and TNF-α are among the first cytokines that
are activated by Ad; they lead to expression of other
downstream factors and also relay signals to the adaptive
immune system [24]. IL-6 and IL-8 play essential roles in the
recruitment of effector cells, such as neutrophils, to liver and
are linked directly to Ad-related hepatic injuries; IL-10 is a key
regulator in development of humoral immunity [10,11,13,34].
As shown in Figure 1B, Ad markedly increased TNF-α, IL-6,
mKC (mouse Keratinocyte-derived Cytokine, analogous to
human IL-8), IL-10 and IL-12p70 secretion at 1- and 6-hour and
IL-1β level 6 hours p.i.; RAPA significantly blocked the
induction of these cytokines. Additionally, the onset of IFN-γ
production was delayed by RAPA from 6 to 12 hours p.i.. Thus,
these results suggest that RAPA treatment can reduce the
Rapamycin in Ad-Based Cancer Imaging and Therapy
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magnitude or delay the onset of components of the Ad-induced
cytokine storm.
Rapamycin potentiated Ad-delivered transgene
expression
Robust and persistent transgene expression is crucial to
ensure diagnostic and therapeutic efficacy of Ads. Therefore,
we set out to determine the impact of the host immune system
on Ad-mediated transgene expression. We injected firefly
luciferase (FL)-expressing Ad into the prostate of
immunocompetent BALBc/129 or severe combined
immunodeficiency (SCID) mice and used in vivo
bioluminescent imaging to monitor FL expression over 5
weeks. As shown in Figure 2A, both the duration and
magnitude of transgene expression were greatly reduced in
BALBc/129 mice that possessed intact immune functions
compared to the SCID mice. Next, we asked if RAPA could
mitigate such inhibitory effects presented by the host adaptive
immune system. As the ultimate goal of this study is to facilitate
the clinical translation of Ads, we examined if RAPA could
augment Ad-mediated cancer imaging using positron emission
tomography (PET), a clinically–relevant imaging modality. The
imaging reporter gene used in this experiment is the HSV1-
sr39tk, an enhanced variant form of herpes simplex virus
thymidine kinase gene, and the probe for this gene is its
substrate 18F-FHBG [35]. RM-9 prostate tumors were implanted
Figure 1.  Rapamycin diminished Adenovirus-induced innate immune response.  (A) BALB/c mice were given daily oral
rapamycin (30 mg/kg) or saline treatment 3 days prior to i.v. injection of 1×109 PFU Ad-CMV-FL or saline. Liver tissues from these
mice were harvested at indicated time points, lysed and subjected to western blot to examine IκBα degradation. β-actin was used as
the loading control. m1, m2 and m3: mouse 1, 2 and 3 in each group at each time point. (B) Sera from these mice were collected at
1, 6 or 12 hours and cytokine levels were assayed by ELISA. Error bars: mean + SEM (n=3). ns, not significant; *, P<0.05; **,
P<0.01; ***, P<0.001 by two-tailed t test compared to Ad only group.
doi: 10.1371/journal.pone.0073650.g001
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in syngeneic, immunocompetent C57BL/6 mice and the tumor-
bearing mice were treated with vehicle or RAPA prior to
intratumoral Ad-CMV-sr39tk injection. PET analysis six days
after viral injection revealed distinctly heightened sr39tk-
specific 18F-FHBG tumoral signal in all four mice in the RAPA-
treated cohort; in contrast, only one mouse in the control group
exhibited weak signal (Figure 2B). These results indicated that
RAPA can potentiate Ad-mediated transgene expression in
immunocompetent hosts, boding well for the utility of combining
this form of transient immunosuppression with Ad diagnostic
imaging approaches in clinical context.
To further assess this combined drug and molecular imaging
approach in clinically relevant scenarios, we asked if the
enhancing effect of RAPA can be extended to animals with pre-
existing anti-Ad immunity. We employed two strains of
immunocompetent mice, C57BL/6 and FVB, and immunized
them with an intraperitoneal (i.p.) dose of 1×108 PFU empty Ad
(experimental timeline shown in Figure 3A). This viral
Figure 2.  Rapamycin mitigated the eliminative effect of
adaptive immune system on Ad-mediated transgene
expression.  (A) 2×108 PFU prostate-specific FL-expressing
Ad was orthotopically injected into the prostate of
immunocompetent BALBc/129 or immunodeficient SCID mice.
FL imaging was performed at indicated time points post viral
administration. Color bar: photons/second/cm2 /sr. (B) Male
C57BL/6 mice carrying subcutaneous RM9 tumors were given
saline or rapamycin treatment for 4 days starting at 7 days post
tumor implantation. Then, 5×108 PFU sr39tk-expressing Ad
was injected intratumorally. PET imaging was performed 6
days later with 18F-FHBG. Subcutaneous tumors were indicated
by red arrows.
doi: 10.1371/journal.pone.0073650.g002
immunization scheme led to the development of robust anti-Ad
humoral immune response in these mice (Figure S1 in File S1).
Syngeneic prostate tumors (RM-9 or MycCaP [36]) were then
established subcutaneously 3 weeks after the primary viral
immunization. The subcutaneous model was chosen over the
orthotopic one for this initial proof-of-principal study due to the
practical feasibility of intratumoral viral administration, tumor
size assessment, as well as the attenuation of the
bioluminescent signals from the deeper prostatic tumors. When
tumors became palpable (4-5 days for RM9; 5-7 days for
MycCaP), daily i.p. injection of RAPA or diluent was
administered. 3 days later, the animals received the secondary
intratumoral injection of FL-expressing Ad (1×108 PFU for RM9;
5×108 PFU for MycCaP). Bioluminescent imaging was
performed to monitor FL expression. In the RM-9 tumor model,
high (5 mg/kg), medium (1.5 mg/kg) and low (0.5 mg/kg) doses
of RAPA were tested; all dosages enhanced FL expression on
day 4 relative to mice that received the diluent (control).
Transgene expression disappeared on day 7 in control mice
but was still detectable in RAPA treated cohorts (Figure 3B). In
the FVB compatible MycCaP tumor model, only 5 mg/kg RAPA
was tested; mice were followed by imaging for 21 days. As
shown in Figure 3C-D, RAPA increased FL expression level on
day 4, and significantly extended transgene persistence for at
least 21 days, which was the last time point tested. Taken
together, our results demonstrate that, even under the
challenge of pre-existing immunity, RAPA can augment the
expression of Ad-delivered imaging reporter gene and prolong
the diagnostic window. These data also support that the
facilitating effects of RAPA are not tumor model- or mouse
strain-specific.
Rapamycin suppressed anti-Ad adaptive immune
responses
To further investigate the mechanism underlying RAPA’s
promoting effects on Ad transgene expression in pre-
immunized hosts, we first examined the titer of anti-Ad
antibodies in mice sera at the end of the previous studies. In
the RM-9 model, both medium and high RAPA doses, but not
the low RAPA dose, prevented secondary production of anti-Ad
IgG in pre-immunized C57BL/6 mice (Figure S2 in File S1). A
trial with larger cohort size revealed that high dose RAPA
reduced IgG titer from 1.36±0.33×105 to 9.88±2.02×103
(P=0.0021, two-tailed t test; n=8) (Figure 4A). Similarly, RAPA
reduced end-point IgG titer by nearly 3-fold in pre-immunized
FVB mice (P=0.0368, two-tailed paired t test; n=3 to 4) (Figure
4A). These data are consistent with prior studies showing
RAPA’s inhibition on Ad-elicited B cell activation and IgG
production [20]. Of note, we focused on titers of IgG over IgM
because IgM secretion preceded that of IgG and was of a lower
magnitude in these pre-immunized animals. In addition,
secondary viral exposure would induce isotype switching to IgG
[37]. Nevertheless, Xu et al. recently reported the inhibitory
effects of natural IgM antibodies on Ad transduction [38]; in
light of these results, we showed that RAPA also exhibited
suppressive effect on the level of IgM that could bind to Ad
(Figure S3 in File S1).
Rapamycin in Ad-Based Cancer Imaging and Therapy
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Next, we explored RAPA’s role in modulating cell-based anti-
Ad immunity [26,28]. Specifically, we assessed both infiltration
and activation of immune cells in Ad-injected tumors. In the
RM-9 model, immunofluorescent staining uncovered greater
infiltration of F4/80 positive macrophages triggered by Ad
injection. However, the macrophage infiltration was markedly
suppressed by RAPA (Figure 4B). We then used flow
cytometry to achieve better quantification of intratumoral
Figure 3.  Rapamycin enhanced Ad-mediated transgene expression in pre-immunized mice.  (A) The timeline for the pre-
immunity models. Animals were primed with an intraperitoneal dose of 1×108 PFU empty Ad and, 3 weeks later, subcutaneous
tumors were inoculated. RM9 tumors became palpable 4-5 days post implantation; MycCaP tumors became palpable 5-7 days post
implantation. At this point, rapamycin or control treatment initiated and intratumoral Ad imaging vectors were administered 4 days
later. Daily rapamycin treatment was continued till the end of the study. FL bioluminescent imaging was conducted at time points
indicated in B and C. (B) FL bioluminescent imaging of RM-9 bearing C57BL/6 mice on day 4 and 7. High: 5 mg/kg/day rapamycin;
Medium: 1.5 mg/kg/day; Low: 0.5 mg/kg/day. n=3. (C) FL bioluminescent imaging of MycCaP bearing FVB mice (n=3 or 4) at
indicated time points. (D) Quantification of imaging signal from C. Color bar of bioluminescent imaging: photon count. Error bars:
mean ± SEM (n=4 for Ad only; n=3 for Ad + RAPA). * P<0.05, ** P<0.01 by two-tailed t test.
doi: 10.1371/journal.pone.0073650.g003
Rapamycin in Ad-Based Cancer Imaging and Therapy
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myeloid cell populations (CD11b+/CSF1R+). Consistent with
the immunofluorescent staining results, RAPA treatment
significantly decreased myeloid infiltration in the tumors (Figure
4C, first panel). Particularly, cells expressing colony-stimulating
factor-1 receptor (CSF1R), a crucial molecule for the
differentiation of the macrophages, DCs, and other myeloid-
derived monocytes [39], were almost completely eliminated by
RAPA (Figure 4C, second panel) in these tumor infiltrating
myeloid cells. Furthermore, both mature (CD69+) and
immature (CD62L+) phenotypes of CD4+ T cells (CD11b-/
CD4+) were decreased by RAPA (Figure 4C, third panel),
implying that both the recruitment and activation of CD4+ T
cells were impeded. CD8+ cytotoxic T cells (CD11b-/CD8+)
also appeared to be reduced by RAPA (Figure 4C, last panel)
although the CD8+ content of RM-9 tumors was very low, and
thus difficult to accurately measure. Interestingly, consistent
with other reports [20], RAPA decreased tumor angiogenesis,
as reflected by reduced staining of the vasculature CD31
marker (Figure 4B), offering another possible mechanism
underlying RAPA’s inhibition of immune cell infiltration and
activation observed in this model.
Next, we sought to determine if RAPA could impact the
reactivity of tumor infiltrating immune cells towards Ad and Ad-
infected, transgene-expressing cancer cells. IFN-γ, a key
regulatory cytokine for T cell development and activation, was
chosen as a readout for immune cell functionality. MycCaP
tumors, established in mice with pre-immunity to Ad, as noted
in Figure 3A and C, were harvested at 1.5 cm diameter and
dissociated to single cells. The dissociated cells were then
incubated with medium or with a “stimulation” cocktail
composed of adenoviral particles and cell lysate from MycCaP
cells infected with FL-expressing virus. IFN-γ production from T
cells upon stimulation was then assessed by intracellular
staining and flow cytometry. As shown in Figure 4D, in the
cohort without RAPA treatment (-, control), Ad-mediated
stimulation resulted in a 35% increase of IFN-γ expression in
CD4+ T cells over the non-stimulated (plain media) baseline;
however, T cells from RAPA treated tumors were not
Figure 4.  Rapamycin suppressed anti-Ad adaptive immune responses.  (A) FVB and C57BL/6 mice were treated according to
the protocol shown in Figure 3A. Mouse serum samples were collected at the end of study and subjected to ELISA for anti-Ad
antibody titration (FVB: means from 3 independent trials; *, P=0.0368 by two-tailed paired t test. C57BL/6: representative data from
2 independent trials (n=10); **, P=0.0021 by two-tailed t test). Error bars: mean + SEM. (B) Representative immunofluorescent
staining of thin sections from RM-9 tumors with indicated treatment. Pink, macrophage marker F4/80; green, blood vessel marker
CD31; blue: DAPI. Scale bar = 200 µm. (C) RM-9 tumor from indicated treatment groups were dissociated and subjected to flow
cytometry analysis for myeloid and T cells populations. Myeloid cell lineage was defined by CD11b staining. Error bars: mean ±
SEM (n=5). ns, not significant; **, P<0.01; ***, P<0.001 compared to Ad only group by two-tailed unpaired t test. (D) MycCaP tumors
from control or rapamycin-treated animals (n=3) were harvested at 1.5 cm diameter, dissociated, and then incubated with plain
media or media containing adenovirus and Ad-infected MycCaP cell lysate for 3.5 hours at 37 °C, stained with intracellular IFN-γ
antibodies and subjected to flow cytometry. IFN-γ expression with stimulation was then normalized to corresponding non-stimulated
control (set as 100%). T cell subsets were delineated by CD4 and CD8 staining. Error bars: mean + SEM (n=3). *, P=0.0431 by two-
tailed unpaired t test.
doi: 10.1371/journal.pone.0073650.g004
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responsive to these stimuli. The reactivity of the rare CD8+ T
cells in MycCaP tumors appeared to be unaltered by RAPA.
Collectively, the addition of RAPA to the Ad-mediated tumor
gene transfer protocol decreased the infiltration of myeloid and
T immune cells in the tumor environment; it also blunted T cell
reactivity towards virus-related stimuli.
Rapamycin potentiated Ad-sr39tk/GCV gene therapy in
pre-immunized mice
Next we tested the ability of rapamycin to augment Ad-
mediated suicide gene therapy via the enhanced herpes
simplex virus thymidine kinase (HSV-tk) gene, sr39tk, and its
prodrug ganciclovir (GCV) [40]. To choose a suitable model to
study sr39tk/GCV-based therapy, the susceptibility of RM9 and
MycCap cells were assessed. Both cell lines were infected by
sr39tk-expressing Ads at a multiplicity of infection (MOI) of 100
and treated by indicated doses of GCV from day 2 to day 7 p.i..
The viability of RM9 cells was not altered by the expression of
sr39tk or the presence of GCV, whereas MycCap cells were
sensitive to this treatment (Figure 5A). Therefore, the MycCap
model is selected; moreover, the PSES-TSTA [3] prostate-
specific promoter exhibited robust transcriptional activity in
MycCap cells (Figure 5A and S4 in File S1) and thus, it will be
used in the following therapeutic experiments.
FVB mice were pre-immunized with empty Ad and inoculated
with subcutaneous MycCap tumors according to the same
protocol as in Figure 3A. The animals then received daily i.p.
treatment of RAPA or diluent for 4 consecutive days when the
tumor became palpable. Then, the animals were given the
secondary intratumoral dose of the therapeutic Ad-PSES-
TSTA-sr39tk. Ad-PSES-TSTA-FL was used as control. RAPA
treatment was continued for another 7 days and 50 mg/kg/day
GCV was provided to the treatment groups till the end of the
study (timeline shown in Figure 5B). Notably, RAPA is a potent
anti-cancer drug itself (Figure S5 in File S1); thus, we
administered the drug transiently for only 7 days post the
secondary viral administration to achieve immunosuppression
without masking the therapeutic impact of Ad-PSES-TSTA-
sr39tk gene therapy. As shown in Figure 5A, although MycCap
cells demonstrated excellent sensitivity to sr39tk/GCV
treatment in vitro, the gene therapy alone only showed
marginal tumor growth inhibition in vivo (Figure 5C). However,
adding RAPA to this regime significantly potentiated sr39tk/
GCV’s therapeutic effects and successfully deterred tumor
growth for as long as 4 weeks post therapeutic Ad
administration, when the study was ended because tumors in
Figure 5.  Rapamycin enhanced sr39tk/GCV gene therapy in pre-immunized FVB mice.  (A) MycCap and RM9 cells were
infected by Ad-PSES-TSTA-sr39tk, Ad-CMV-sr39tk or no virus at MOI=100 and treated by indicated concentrations of GCV from
day 2 to day 7 p.i.. Cell viability was measured by CCK-8 assay on day 7 and normalized to the no-virus, zero GCV condition (the
dashed line). Experiments were performed in duplicates. Shown are representative results from 3 independent trials. (B) The
timeline for the therapeutic study (see text). (C) Tumor growth determined by caliper measurements twice per week. n=4 for the
Control and RAPA groups; n=7 for the Gene Therapy (Ad-PSES-TSTA-tk/GCV) and combinational therapy (RAPA+Ad-PSES-
TSTA-tk/GCV) groups. Tumor volume = length×(width)2 ×0.52. ***, P<0.0001 by two-way ANOVA comparing the combinational
group against Control, RAPA and Gene Therapy cohorts.
doi: 10.1371/journal.pone.0073650.g005
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the other cohorts reached the 1.5 cm ethical limit of tumor
growth (Figure 5C).
Discussion
In terms of utilizing immunosuppressant in cancer gene
therapy trials, low dose cyclophosphamide has been exploited
to augment oncolytic adenoviral gene therapy in Syrian
hamster models [41,42]. Cyclophosphamide has also been
used as an immunomodulator to specifically inhibit regulatory T
cells, sparing effector T cells, and thereby boost anti-tumoral
immunity elicited by oncolytic Ad or IL-12 expressing vectors in
several trials of solid tumor gene therapies in mice and humans
[43,44]. The combined use of rapamycin with oncolytic Ad was
also explored in one previous study to treat colon cancer [20],
where RAPA decreased anti-Ad antibodies and enhanced
intratumoral viral retention by inhibiting angiogenesis, and
consequently improved therapeutic outcome. The present
study, however, is the first to provide a comprehensive
evaluation of RAPA’s effects on moderating Ad-related immune
responses (including innate, humoral and cellular adaptive
responses) in pre-immunized murine hosts. These results are
relevant to clinical translation of Ad in that they shed light on
issues such as drug safety, vector clearance, duration of
transgene expression and repeated vector administration.
Short-term pretreatment with RAPA markedly attenuated Ad-
induced NF-κB activation and the cytokine response, thus
could improve the safety profile of Ad vectors (Figure 1). Of
note, these benefits are readily applicable to trials involving
second and third generations (helper-dependent) of Ad vectors,
because the innate immune response is provoked solely by Ad
capsid proteins [19]. Also, unlike prior studies that targeted
single inflammatory pathways [8,9,11], RAPA inhibits the
expression of a broad panel of cytokines/chemokines and the
activation of a diverse repertoire of immune cells (Figures 1
and 4). Because mTOR function is involved in nearly all cell
types, RAPA usage may raise the concern of side effects.
However, we did not observe any standard signs of morbidity
(e.g., hunched back, sunken eyes, dehydration or lethargy) in
RAPA cohorts although an expected reduction of 15-18% of
body weight did occur due to RAPA’s suppression on cell size
and metabolic rate [30].
PET imaging, a modality that enables molecular pathway
interrogation in tumors in living subjects, is widely used in
clinics. However, due to its low sensitivity compared to
bioluminescent imaging, Ad-directed reporter gene-based PET
imaging usually demands the administration of a high dose of
vector. We show here that RAPA allowed us to achieve
unambiguous tumor detection with a relatively low dose of Ad
(5×108 PFU, Figure 2B), a viral load well below the lethal dose
in mice (5-10×109 PFU). These data illustrate the viability of
incorporating RAPA into Ad-mediated imaging regimens, so
that a lower and thus safer viral dose is sufficient to achieve
cancer detection.
In the HSV-tk mediated suicide gene therapy scenario,
factors such as vector immunogenicity, magnitude of suicide
gene expression and cellular susceptibility can all impact
overall therapeutic efficacy. For instance, MycCap cells are
highly susceptible to sr39tk/GCV treatment in vitro. However,
when the same treatment was implemented in vivo in pre-
immunized FVB mice, only marginal therapeutic effects were
achieved (Figure 5C). This is likely due to blockade of
transduction, premature viral clearance and/or the elimination
of transgene-expressing cells resultant from the activation of
innate, humoral and cell-mediated immunity that we have
shown that is at play in the pre-immunized hosts after the
secondary viral challenge. The incorporation of RAPA into the
treatment regimen, however, significantly improved the
therapeutic effect of Ads, resulting in complete tumor-stasis
(Figure 5C). Another notable reason for the lack of response of
RM9 cells to sr39tk/GCV could be attributed to the weak
activity of the chimeric prostate-specific PSES promoter in this
cell line as the RM9 line is known to be weakly regulated by
androgen [32]. As shown in Figure S4 in File S1, reporter
assays revealed that the magnitude of gene expression in RM9
cells from either the CMV or the PSES-TSTA promoter was
nearly 100 folds lower than that of the PSES-TSTA in MycCap
cells.
Of note, other non-immunosuppressive measures have been
undertaken to tackle host immune reactions against Ad. For
example, serotypes of less prevalent Ad have been exploited to
reduce recognition and neutralization by anti-Ad5 antibodies
[45]. Fiber and hexon manipulations have also been attempted
to modulate viral interaction with target cells, seeking reduction
of immune response and hepatic injury [7,13,46]. Moreover,
even though host immune systems present the most
formidable obstacle for Ad vectors, there are other factors
contributing to the impediment in their clinical application. For
instance, over 90% of i.v. Ad dose will be sequestered in the
mouse liver due to Kupffer cells entrapment, RGD-integrin
bridged endothelial cell infection and hepatocyte transduction
that may be mediated by coagulation factor-heparan sulfate
interactions [38,47–52]; this liver tropism unfavorably diverts
the biodistribution of Ad vectors and restrains their access to
cancer sites. This problem can be partially evaded by
eliminating Kupffer cells with a pre-dose of virus [3,50,53],
chemical compounds [7,54,55], or inhibiting coagulation
factors’ activity by warfarin treatment. The issue of vector
sequestration in liver remains a very active area of
investigation. Additionally, various non-viral polymer- and
nanoparticle-based strategies have been investigated to
mitigate immune reactions against Ads [56–58]. Another
daunting challenge specific to humans is that human
erythrocytes express the major receptor for Ad – Coxsackie
virus-adenovirus receptor (CAR). This can lead to trapping and
inactivation of the majority of i.v. delivered Ad5 [59]. The
complement receptor on human erythrocytes also contributes
to the elimination of Ad vectors [59]. Overall, these questions
deserve further investigations by alternative approaches that
include Ad surface modification, development of hybrid
serotypes and liver de-targeting tactics. Meanwhile, more
human-related experimental models need to be established to
mimic these challenging situations.
In summary, we report in this study the use of rapamycin
alleviated Ad-induced inflammation. We observed several
benefits of rapamycin treatment, including the suppression of
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Ad-elicited myeloid and T cell infiltration, lowered anti-Ad
antibody production and T cell function. The collective effects
of rapamycin treatment are a clear improvement in the imaging
capability and therapeutic effects of Ad vectors in
immunocompetent and pre-immuned hosts. This study offers a
viable strategy to integrate transient immunosuppression into
Ad-mediated cancer diagnostic and therapeutic applications to
facilitate the successful future clinical translation of Ads.
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